How many years of life can be extended after treatment with Sotolaxib?

Sotorasib is a targeted drug targeting the KRAS G12C mutation. It is mainly used to treat patients with non-small cell lung cancer (NSCLC) who carry this mutation. KRAS is one of the common driver gene mutations in lung cancer, and G12C mutation has long been considered an "undruggable" target. The emergence of sotoracib breaks this limitation, provides new treatment opportunities for these patients, and becomes the first targeted drug approved in the world for KRAS G12C mutated lung cancer.

Regarding the issue of life extension, according to clinical trial data, patients treated with sotoraxibKRAS The median progression-free survival (PFS) of patients with G12C mutations is 6.3 months, and the median overall survival (OS) is approximately 12.5 months. In other words, after using this drug, most patients can achieve short-term stabilization of the disease and extend their lives by about one year. This is already a significant clinical improvement for patients with advanced lung cancer, especially after failure of standard treatments.

However, the life extension brought about by Sotoracib is not a fixed number of years but varies from person to person. Some patients respond well to treatment and can gain survival benefits of more than one year or even longer, while a small number of patients may stop treatment early due to drug resistance or other factors. Overall, the drug does not "cure" cancer, but it does provide a relatively effective new option for patients with KRAS G12C mutations.

It is worth emphasizing that the efficacy of sotoracib is closely related to multiple factors such as the patient's constitution, tumor burden, and previous treatment history. Clinicians usually combine genetic test results with the overall condition to determine whether the drug is suitable for use. In the future, if it can be combined with other treatment strategies, such as immunotherapy or other targeted drugs, it is expected to further improve the efficacy of sotorasib and prolong the survival of patients.

Reference materials:https://www.lumakras.com/